Immunization in India with trivalent and monovalent oral poliovirus vaccines of enhanced potency.
Bull World Health Organ
; 54(1): 115-7, 1976.
Article
en En
| MEDLINE
| ID: mdl-1087587
In an attempt to improve the serological response of infants in warm climates to oral poliovirus vaccine (OPV), the authors administered to 79 children between 6 and 41 weeks of age trivalent and monovalent OPV containing a virus dose 10 times as high as that found in the standard vaccine. The seroconversion rates following one dose of this trivalent OPV were 42% to type 1 poliovirus, 85% to type 2, and 31% to type 3. These rates are only slightly better than those previously reported after one dose of standard trivalent OPV and much lower than those achieved after 3 doses. The seroconversion rates following one dose of the monovalent OPV of enhanced potency were 89%, 93%, and 76%, respectively. These rates are comparable to those achieved after 5 doses of the standard trivalent OPV. Thus the refractoriness of host response was only partly overcome by enhancing the virus inoculum 10-fold.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Vacuna Antipolio Oral
Límite:
Female
/
Humans
/
Infant
/
Male
País/Región como asunto:
Asia
Idioma:
En
Revista:
Bull World Health Organ
Año:
1976
Tipo del documento:
Article
Pais de publicación:
Suiza